Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,469.00+3.46%ETH$2,428.17+5.94%GOLD$4,072.20+3.34%OIL$88.04-8.38%
Smart Investors Daily
SID Premium
RV

NASDAQ · RVMDW

Revolution Medicines, Inc. Warrant

Healthcare · Biotechnology

$10.18

Up+$0.50 (+4.91%)

Updated Nov 4, 2026, 10:22 PM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
154.68M
P/E ratio
-15.46
Dividend yield
0.00%
52-week range
$1.53 – $13.44
Volume
8.95K
Avg. volume
28.36K

Price performance · RVMDW

RVMDW price history

1M range · 0 trading sessions · Daily adjusted prices

RVMDW does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest RVMDW news

The latest Smart Investors Daily articles mentioning RVMDW.

Stock researchCompany · Overview

RVMDW research

Overview

Company profile and research snapshot.

Company profile

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival benefit compared with chemotherapy across key subgroups, including patients with no identified tumor RAS mutation​Findings presented as late-breaking abstract during Proffered Paper session REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commerc

Yahoo · Oct 23, 2026

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib Vopimetostat combinations with RAS(ON) inhibitors daraxonrasib or zoldonrasib continued to be generally well-tolerated Registrational Phase 3 study of vopimetostat plus daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer expected to be initiated in 1H 2027 Investor webcast focused

Yahoo · Oct 21, 2026

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a

Yahoo · Oct 20, 2026

Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment

Revolution Medicines Inc. (NASDAQ:RVMD) began treating patients in its global Phase 3 clinical study, RASolve 308, to evaluate a combination treatment for metastatic lung cancer. The trial tests the company’s investigational therapy, zoldonrasib, alongside standard care as a first-line treatment for adults with non-squamous non-small cell lung cancer harboring the RAS G12D mutation. Read Also: Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow Phase 3 Study Des

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By